Orchard Therapeutics plc American Depositary Shares
ORTX
ORTX was delisted on the 23rd of January, 2024.
72 hedge funds and large institutions have $84.6M invested in Orchard Therapeutics plc American Depositary Shares in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 14 increasing their positions, 26 reducing their positions, and 24 closing their positions.
9% less funds holding
Funds holding: 79 → 72 (-7)
25% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 24
46% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 26
49% less capital invested
Capital invested by funds: $167M → $84.6M (-$82.8M)
53% less call options, than puts
Call options by funds: $82K | Put options by funds: $175K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.92M |
| 2 |
CA
CHI Advisors
New York
|
+$3.92M |
| 3 |
SG Americas Securities
New York
|
+$1.07M |
| 4 |
Two Sigma Investments
New York
|
+$897K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$576K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$8.82M |
| 2 |
CC
Casdin Capital
New York
|
-$5.92M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.06M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$3.05M |
| 5 |
JP Morgan Chase
New York
|
-$2.27M |
ORTX Hedge Fund Activity: Q4 2021 in Review
72 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q4 2021, worth a combined $84.6M — down 49% from $167M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ORTX and 18 opened new positions — a net loss of 6 holders — while 26 trimmed existing stakes and 14 added.
The largest buyer was Federated Hermes, adding an estimated $3.92M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $8.82M sold.
- 72 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q4 2021, down from 79 in Q3 2021.
- Funds reported $84.6M of Orchard Therapeutics plc American Depositary Shares stock for Q4 2021, down 49% quarter-over-quarter.
- 18 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q4 2021 and 24 closed out, a net change of -6 holders.
- The largest Orchard Therapeutics plc American Depositary Shares buyer in Q4 2021 was Federated Hermes, an estimated $3.92M added.
- The largest Orchard Therapeutics plc American Depositary Shares seller in Q4 2021 was Avidity Partners Management, an estimated $8.82M sold.
Based on aggregated 13F filings for Q4 2021.